Hemochromatosis is a common genetic disorder in which iron may progressively accumulate in the liver, heart and other organs. The primary goal of therapy is iron depletion to normalize body iron stores and to prevent or decrease organ dysfunction.
The primary therapy to normalize iron stores is phlebotomy. In this opinion paper, we discuss the indications for and monitoring of phlebotomy therapy to achieve iron depletion, maintenance therapy, dietary and pharmacological maneuvers that could reduce iron absorption, and the role of voluntary blood donation.
Introduction
Hemochromatosis is a common heritable disorder characterized by the progressive accumulation of iron due to increased absorption from dietary sources. 1 The most common hemochromatosis genotype is homozygosity for HFE C282Y, although the role of HFE protein in the pathogenesis of the iron overload has not been clearly elucidated.
Other mediators that affect iron absorption, transport, and mobilization include hepcidin, bone morphogenic protein 6, hemojuvelin, transferrin receptor-1 and -2, and ferroportin. 2 The use of phlebotomy therapy to reduce body iron stores followed the clinical description of hemochromatosis by at least 50 years. 3 Phlebotomy stimulates erythropoiesis and mobilizes iron from parenchymal cells and other storage sites.
In this opinion paper, we focus on the treatment of typical HFE C282Y homozygotes with iron overload. Many of these management concepts are also applicable to the treatment of patients with other types of iron overload, although the severity of iron overload and response to phlebotomy vary depending on the genetic subtype of hemochromatosis or other iron overload disorder. Further, the success of phlebotomy therapy depends on normal erythropoiesis. The diagnosis of iron overload is beyond the scope of this article. 4 More patients have hyperferritinemia that is due to inflammatory conditions and liver diseases than to iron overload, and the risk for adverse events caused by inappropriate phlebotomy therapy in such patients may be great. Phlebotomy treatment of other conditions such as hepatitis C, fatty liver disease, and porphyria cutanea tarda is beyond the scope of this article.
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Rationale for iron depletion therapy
It had been previously considered that most hemochromatosis patients have progressive iron accumulation. Excess iron is toxic to cells, an effect mediated through the production of free radicals and the Fenton reaction, 5 although many in vitro iron toxicity studies used supra-physiological concentrations of iron. The previous rationale for phlebotomy therapy for all patients with hemochromatosis was that iron depletion would reduce or eliminate the potential for iron-mediated tissue injury.
6
, Iron toxicity has been difficult to demonstrate in animal models. 7 An extrapolation unfounded by clinical studies was that iron depletion would improve the quantity and quality of life of all hemochromatosis patients, and that the benefits of therapy would outweigh any potential risks or adverse effects of phlebotomy therapy.
Do all C282Y homozygotes require phlebotomy therapy?
Since the development of diagnostic genetic testing for hemochromatosis, it has become apparent that approximately 50% of female and 20% of male adult C282Y homozygotes have normal serum ferritin (SF) levels and may never require phlebotomy therapy. 8 The guidelines for the initiation of phlebotomy therapy published by expert groups before HFE mutation analysis was widely available recommended starting therapy in C282Y homozygotes with an elevated SF (>200 µg/L in women, >300 µg/L in men). 9 This recommendation stems from the assumption that a person with hemochromatosis and an elevated SF level at presentation has already demonstrated accumulation of excess iron which would likely be progressive. Because most patients have been treated with phlebotomy after clinical or biochemical presentation, there has
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From been little opportunity to collect observations on the natural history of untreated hemochromatosis. Several large population-based studies have performed hemochromatosis genetic testing on participants many years into the study and used stored blood samples to measure SF over time in participants found to have C282Y homozygosity. [10] [11] [12] [13] [14] [15] These studies demonstrate that not all C282Y homozygotes, including those with an elevated SF level, are destined to have progressive iron overload. 16;17 The degree of elevation of the SF level at presentation can be used to predict the risk of progression. 13 An adult C282Y homozygote with a normal SF level at diagnosis is very unlikely to develop iron overload later. 14 These observations from population screening studies may not be relevant to a C282Y homozygote with symptoms referred to initiate phlebotomy therapy. It is widely agreed that persons with hemochromatosis whose SF is ≥1000 µg/L should undergo phlebotomy to achieve iron depletion. 18 The decision to treat C282Y homozygotes with moderate elevations of SF (200 -1000 µg/L) should consider patient preferences and clinical judgment ( Table 1) .
The conventional approach is to treat all C282Y homozygotes with SF above the reference range. New information from population studies has demonstrated that SF levels do not rise progressively in all patients, and thus observation with follow-up SF measurements can be considered as an alternative management strategy. The presence of symptoms or elevated serum levels liver enzymes are not a prerequisite for initiating phlebotomy therapy.
Clinical benefits of phlebotomy therapy
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From A randomized study of phlebotomy therapy has not been done; therefore, it has been difficult to assess the clinical benefits of therapy. In a large survey of hemochromatosis patients in the U.S. and Canada, 76% of patients received phlebotomy in a hospital or physician's office and 30% at a blood center. More than three-quarters of patients reported that their phlebotomy therapy was beneficial, whereas 15% expressed a negative opinion about therapy. The primary negative aspects were venous access problems, time (for travel, waiting, and the procedure), and the fact that in many cases the blood is not used for donation. Fifty-nine percent reported that if they could take a pill with a 5% chance of serious adverse effects, they would prefer that treatment to phlebotomy. 19;20 Liver fibrosis, cirrhosis, and hepatocellular carcinoma are the most serious complications of iron overload. In population-based studies, these complications occur in ~5% of male and <1% of female C282Y homozygotes. 21;22 The presence of symptoms related to iron overload in C282Y homozygotes found in a population screening study was 28.4% in men and 1.2% in women. 21 Several studies that evaluated liver biopsies before and after phlebotomy therapy demonstrated that hepatic fibrosis can be reversed by phlebotomy therapy. 23;24 Hepatic elastography is a noninvasive tool that may be useful to monitor this potential benefit without the need for liver biopsy. 25 Liver biopsy has moved from a diagnostic test to a prognostic test in many patients with hemochromatosis. It should be considered in C282Y homozygotes with SF ≥1000 µg/L, and in patients with non-iron risk factors for liver disease (e.g., alcohol, obesity, viral hepatitis). Liver iron concentration was most useful when the iron g/dL, the treatment schedule is modified to 500 mL every other week; lower volumes (250-400 mL per session) are optimal for some persons of small body habitus or those whose hemoglobin levels are restored slowly after phlebotomy. Pre-treatment hydration and the concomitant administration of a salt-containing sport beverage (e.g., Gatorade®) is a simple method of maintaining plasma volume during and after phlebotomy treatments.
Monitoring iron measures during phlebotomy therapy
Management of iron overload is based on measurements of SF because these measures are directly related to the amount of stored iron. Accordingly, we quantify SF every month (or after every four phlebotomy sessions) in patients with hyperferritinemia undergoing therapy to induce iron depletion. After SF levels are <200 µg/L, we measure SF every 1-2 weeks (or after every one-two phlebotomy sessions).
Transferrin saturation is elevated in most patients with hemochromatosis who have hyperferritinemia due to iron overload, although day-to-day values fluctuate in the same person. Plasma iron species unassociated with ferritin or transferrin occur in some persons with hemochromatosis, typically when transferrin saturation is elevated. These include non-transferrin-bound iron (NTBI) and labile plasma iron (LPI). Both may promote tissue overload and consequent damage.
35-39 NTBI and LPI are mainly found when transferrin saturation exceeds 45% and 75%, respectively, 39 although NTBI 1 1 persists in some subjects with low serum iron level and high serum iron-binding capacity. 40 Thus, measurement of transferrin saturation during phlebotomy to achieve iron depletion would provide surrogate qualitative assessments of NTBI and LPI.
Regardless, no bioclinical correlate of either NTBI or LPI has been reported in HFE C282Y homozygotes, nor is there evidence-based management to reduce NTBI and LPI other than iron depletion.
Endpoints of phlebotomy therapy
There are different ways to follow the progress of phlebotomy therapy. At our centers, patients are treated until the SF is ~50 µg/L, a value in the lower reference range that signifies that there is little or no storage iron. Lynch and colleagues measured iron absorption from test meals in hemochromatosis patients who were untreated (SF >1000 µg/L), partially treated with phlebotomy (mean SF 538 µg/L; range 210-786 µg/L), and "fully" treated by phlebotomy (mean SF 14 µg/L; range 10-21 µg/L). 41 Non-heme iron absorption was 9%, 12%, and 42% in these respective groups, whereas heme iron absorption was 41%, 50%, and 39%. These results demonstrate that non-heme iron absorption is markedly increased by phlebotomy that results in SF ~20 µg/L, and could lead to unnecessary induction and maintenance phlebotomy. The absorption of heme iron is relatively high but stable, regardless of the magnitude of iron stores. Accordingly, the SF ~50 µg/L criterion enhances absorption of non-heme iron less than would occur at SF ~20 µg/L, and allows some "room" for iron re-accumulation into the mid-or upper reference range. The decrease in SF levels with phlebotomy is infrequently linear; the rate of iron mobilization may be higher in patients with cirrhosis. 42 There are significant subacute iron toxicity or organ dysfunction. The value of maintenance phlebotomy therapy to keep iron stores within the reference range has not been clearly established.
We advise patients who had symptoms or signs reasonably attributable to iron overload at diagnosis that were alleviated by iron depletion and those with SF ≥1000 μg/L at diagnosis to maintain low iron stores with periodic phlebotomy. Reports of achieving and maintaining low iron stores in hemochromatosis patients who also have common liver disorders such as non-alcoholic steatosis or hepatitis C reveal inconsistent results.
49;50
Iron accumulation rates vary greatly amongst C282Y homozygotes; this variability persists after iron depletion. Women are less likely than men to re-accumulate iron rapidly. Some patients with hemochromatosis monitored as long as 11 years after initial iron depletion and not treated with maintenance therapy did not re-accumulate iron. 51 We advise measuring SF six months after cessation of therapy to estimate the risk of iron re-accumulation and to personalize maintenance therapy based on these observations.
Intolerance of phlebotomy
Decreasing the phlebotomy interval to every two weeks is necessary in some patients, especially women. 9 In patients who report hypotension or dizziness, the volume of oral salt drinks can be increased; rarely, an intravenous saline solution must be infused to restore blood volume after phlebotomy. The volume of blood removed can be decreased, but this prolongs the overall duration of therapy to achieve iron depletion. Performing TE requires the apheresis apparatus itself, a skilled technician, careful patient selection, and venipuncture with large-bore needles to accommodate the flow and pressure requirements of apheresis machines. Patients with hemochromatosis treated with erythrocytapheresis to achieve iron depletion should have pre-procedure hemoglobin ≥12 g/dL. The volume of erythrocytes removed at each treatment should be adjusted based on consideration of gender, height, weight, and pre-treatment hematocrit, such that the minimal post-procedure hematocrit is 30%; patients with postprocedure hypovolemia benefit from infusion of normal saline. Additional procedures are performed every two weeks in persons whose hemoglobin level has returned to ≥12 g/dL; an interval of three weeks between procedures is required in some patients, especially women. SF is monitored in the same manner as previously described for therapeutic phlebotomy. 54;56;57 TE achieves iron depletion in persons with hemochromatosis in a shorter treatment period than therapeutic phlebotomy. 56 In a pilot study of six hemochromatosis patients treated with TE, the total number and the duration of treatments in the TE group was ~70% lower than that in historical control subjects managed with therapeutic phlebotomy. Although the costs of a single TE session were higher, the total costs to induce iron depletion were similar to or lower than those with therapeutic phlebotomy.
56
TE appears to be safe and rapid, and may achieve iron depletion in patients with severe iron overload more rapidly than phlebotomy therapy. Regardless, the availability of and clinical experience with TE for management of iron overload due to hemochromatosis
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Medications
Iron chelation drugs. Deferoxamine (DFO), a parenterally administered iron chelator, induced iron depletion in patients with hemochromatosis who were unable to undergo phlebotomy therapy. 58 In short-term studies, DFO treatment was as effective as phlebotomy of 500 mL weekly in removing iron from the liver. 58 Much experience with the poor compliance and acceptability of DFO therapy in patients with nonhemochromatosis iron overload suggests that DFO treatment would not be generally satisfactory for persons with hemochromatosis (Table 1) .
Deferasirox (DFX), an oral iron chelator, was administered daily for 24 weeks to hemochromatosis patients with HFE C282Y homozygosity, pre-treatment SF 300-2,000 µg/L, transferrin saturation >45%, and no history of cirrhosis in a phase I/II study (Table   1) ; one of us was an investigator in this clinical trial. 59 The primary endpoint was the incidence and severity of adverse events; secondary endpoints were change in SF, time to SF normalization (<100 µg/L), longitudinal course of SF, and pharmacokinetics of DFX. Adverse events, documented in <10% of patients, included diarrhea, nausea, abdominal pain, and elevated serum ALT or creatinine levels. These events were doserelated and resolved with dose reduction or cessation of DFX therapy; 77% of patients who were treated initially completed the study. Time course of the decline in SF was
dose-dependent. Only the 5 and 10 mg/kg/d doses are being considered for further study in HFE hemochromatosis, largely due to the rate of adverse events at higher doses.
59
There are no reports of the treatment of HFE hemochromatosis with the oral iron chelator deferiprone (DFP). The combination of DFO and DFP have been used to treat severe iron overload complicated by cardiomyopathy in a patient with a juvenile hemochromatosis phenotype. 60 DFP is not licensed in the U.S.
Phase III trials comparing phlebotomy with oral chelation therapy should be conducted, but may need to await a means to detect which C282Y homozygotes will develop progressive, injurious iron overload and therefore potentially benefit from treatment.
Clinical trials must be designed to determine if oral chelation therapy can eliminate hepatic iron deposits without causing additional liver injury, and if hepatic fibrosis and cirrhosis caused by iron overload can be reversed. 61 Treatment schedules for maintaining low body iron stores after iron depletion has been achieved must also be established. homozygotes could either diminish the severity of iron overload that would otherwise occur due to excess absorption of inorganic iron from dietary sources, or reduce requirements for maintenance phlebotomy. Regardless, there are insufficient data to recommend the routine administration of proton-pump inhibitors to patients with hemochromatosis for the purpose of decreasing iron absorption. Histamine receptor-2
61

Proton pump inhibitors (PPIs
antagonists reduced dietary iron absorption in short-term studies of persons without hemochromatosis, 65 but continuous use of cimetidine for three years did not alter hemoglobin or plasma iron levels significantly. 66 The greater influence of PPIs than histamine receptor-2 antagonists on SF levels could be explained by the direct inhibition of gastric acid secretion and longer duration of action characteristic of PPIs.
Dietary management
Evidence-based dietary advice for patients with hemochromatosis could diminish the rate of increase in iron stores, and decrease the expressivity of iron overload due to hemochromatosis in populations. The rate of compliance with recommended changes in diet in Australian HFE C282Y homozygotes detected in workplace screening was high. 67 Our dietary management recommendations are displayed in Table 2 .
Iron. Absorption of heme and non-heme iron from unfortified test meals is far greater in hemochromatosis patients diagnosed in medical care than would be predicted from the relationship between iron absorption and SF levels observed in normal volunteers.
41;68
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Further, there is a significant inverse relationship of absorption of non-heme iron with increasing SF levels. In contrast, heme iron absorption was not significantly related to SF levels. 41 In women in the U.K., HFE C282Y homozygotes had SF concentrations 2.4 times higher than women with wild-type HFE genotypes. The association of heme iron intake with SF levels estimated using food frequency questionnaires (from meat, fish, and poultry) was 2.0 times greater (range 1.2-3.2) in C282Y homozygotes than subjects with other HFE genotypes; estimated non-heme iron intake had little effect on SF Black tea inhibits the absorption of non-heme iron, presumably due to the intraluminal binding of iron by tannate. In 18 German patients with hemochromatosis, iron absorption was significantly lower when a test meal was accompanied by drinks of tea instead of water. After iron depletion was achieved by phlebotomy in the same patients, regular tea drinking with meals reduced the frequency of maintenance phlebotomies required during an interval of one year. 86 In Australian subjects, reports of tea consumption on a food questionnaire were not significantly associated with SF concentrations, regardless of HFE genotype.
73
Reports of higher levels of non-citrus fresh fruit intake were associated with significantly lower SF levels in men in Busselton, Australia, irrespective of HFE genotype. Mean SF levels were lower by 20% in men who consumed two or more pieces of fruit per day, on average, than in those whose average consumption was less than one piece of fruit daily. This effect was not observed in women. Consumption of citrus fruits and citrus juices had no significant effects in either sex. 73 We advise patients to limit their intakes of supplemental vitamin C to 500 mg daily. In practice, some U.S. blood banks obtained the variances, are involved in therapy of patients with hemochromatosis, and report informally that such patients supplement their blood supplies. Most patients treated at blood banks must undergo SF and other evaluations at the offices of their physicians. We have also encountered patients who donated blood for transfusion without revealing their diagnosis of hemochromatosis and without obtaining SF measurements from their physicians, presumably due to financial considerations. Some have had symptomatic iron deficiency with anemia; others had uncontrolled iron overload. Many U.S. blood banks have declined to obtain the variances and prefer to obtain blood units solely from volunteer donors. 
Summary
For most hemochromatosis patients, standard therapy is the weekly removal of blood to bring the SF level into the low reference range. The major medical benefit of this therapy is the prevention or reversal of liver fibrosis; some patients report decreased dyspnea, pigmentation, fatigue, or arthralgia, or improved control of diabetes mellitus.
The natural history of untreated hemochromatosis has demonstrated that some patients do not have progressive iron overload. Iron chelation therapy is rarely ideal for hemochromatosis patients due to cost, potential toxicity, and relative lack of documentation of benefits. Dietary restrictions and medications to reduce iron absorption seem rational, but have not been evaluated in prospective randomized clinical trials. Future studies that would enable us to predict the progression of iron overload in an individual C282Y homozygote could lead to personalized therapeutic approaches.
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